TSHA

Taysha Gene Therapies, Inc. (TSHA) Risks & Opportunities Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Financial Strength

Very strong liquidity with a current ratio of 17.8x and cash ratio of 17.5x.

Low leverage with debt-to-equity of 0.14x and debt-to-assets of 0.12x.

Net current asset value remains positive at $378.3M.

Profitability

Margins remain deeply negative, with operating margin at -27.9% and net margin at -27.3%.

Returns are still poor, including ROE of -56.2% and ROIC of -34.5%.

Gross margin is high at 84.0%, but it is not yet translating into bottom-line profitability.

Valuation

Valuation remains highly stretched on sales, with price-to-sales at 375.0x and EV-to-sales at 302.1x.

Negative earnings and cash flow keep traditional earnings and FCF multiples difficult to interpret.

Price-to-book is 6.1x, which is elevated for a company still posting losses.

Cash Flow

Operating cash flow is negative, with OCF per share at -$0.36 and free cash flow per share at -$0.37.

Free cash flow and operating cash flow yields remain negative, indicating ongoing cash burn.

Capex is modest relative to operating cash flow, but the business is still not self-funding.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Taysha Gene Therapies, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →